Page 7 - reflections_dyslipidaemia_newsletter7_2024
P. 7
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #7 2024
Compared with children and adolescents who had
been initially identified as having FH via genetic Dyslipidaemia
testing or the Simon Broome clinical criteria, those
who had been initially identified as having FH with
the Dutch Lipid Clinic Network Score (DLCN) or
Make Early Diagnosis to Prevent Early Deaths
(MEDPED) clinical criteria, which has not been
adapted for children or adolescents, had higher
median LDL-C concentrations.
The authors note that compared with genetic
diagnosis, the use of unadapted clinical criteria
intended for use in adults and reliant on more
extreme phenotypes could result in 50%–75%
of children and adolescents with FH not being
identified.
Among children and adolescents taking lipid-lowering medication (LLM), a larger proportion of boys attained LDL-C targets than girls.
Children taking LLM were largely on monotherapy at registry entry and still had high LDL-C concentrations. The authors note that
increased use of combination therapies might help achieve guideline targets.
Likelihood of having LDL-C <3·4 mmol/L among children and adolescents taking LLM.
TABLE OF CONTENTS
